Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 348 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Dementia (AD) Clear all
Terminated No phase listed Observational

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

NCT05097131
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Chula Vista, California • Valencia, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

NCT04795466
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Canakinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)

NCT06850870
View directory record Official record
Conditions
Alzheimer Disease or Associated Disorder, Dementia, Cognitive Decline
Interventions
Door-through-door companion rideshare, Curb-to-curb rideshare services
Other
Lead sponsor
Onward Health, Inc
Industry
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Leandro, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Music, Social Attention, and Dementia

NCT06768996
View directory record Official record
Conditions
Frontotemporal Dementia, Alzheimer Disease
Interventions
Synchronous Rhythm Production, Solo Rhythm Production
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

NCT04867616
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Bepranemab
Other · Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
50 Years to 80 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Fresno, California • Fullerton, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation

NCT06234930
View directory record Official record
Conditions
Healthy Aging, Alzheimer's Disease
Interventions
Audiovisual stimulation VR system
Device
Lead sponsor
Clarity Health Technologies, Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Portola Valley, California • Leesburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Locus-coeruleus Function in Normal Elderly and AD Risk

NCT04403165
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Nocturnal polysomnography (NPSG), Lumbar Puncture (LP), PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB), Psychomotor Vigilance Task (PVT)
Procedure · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational

Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans

NCT03287765
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
65 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 21, 2026, 9:03 PM EDT
Not listed Phase 1 Interventional

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

NCT04500847
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
Interventions
Emtriva Capsule, Placebo
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain

NCT00287248
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] IMPY & SPECT Imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional

A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease: Implementation Phase 2

NCT06368115
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Educational Materials
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
50 Years and older
Enrollment
11,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

NCT04733989
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Assessing a Novel Virtual Environment That Assists With Activities of Daily Living

NCT05418296
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Neurodegenerative Diseases
Interventions
A novel digital health device
Device
Lead sponsor
mandy
Industry
Eligibility
Up to 110 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Elk Grove, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 21, 2026, 9:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)

NCT00973518
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2010 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Early Phase 1 Interventional

PET Imaging of Subjects Using 124I-PU-AD

NCT03371420
View directory record Official record
Conditions
Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
Interventions
PU-AD, PET Scan, Blood Draws
Drug · Device · Other
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
21 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT05557409
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Peoria, Arizona • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

NCT02912169
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Liposuction under local anesthesia, Infusion of AD-SVF via IV and Intranasal
Procedure · Biological
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

NCT02880956
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABBV-8E12, placebo for ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 85 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 21, 2026, 9:03 PM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

NCT06736509
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Peoria, Arizona • Walnut Creek, California • Bonita Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

"Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program"

NCT05350410
View directory record Official record
Conditions
Dementia, Alzheimer's Disease, Dementia Prevention
Interventions
HALT-AD
Behavioral
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

NCT07651319
View directory record Official record
Conditions
Alzheimer Dementia (AD)
Interventions
IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 9:03 PM EDT